

**Amendments to the Claims**

Please cancel claims 5-17 without prejudice. Please amend claims 1-4 as follows:

Claim 1 (currently amended): A recombinant LK6 polypeptide consisting of amino acid sequence of SEQ ID NO:4, ~~and having anti-angiogenic activity.~~

Claim 2 (currently amended): A recombinant LK7 polypeptide consisting of amino acid sequence of SEQ ID NO:6, ~~and having anti-angiogenic activity.~~

Claim 3 (currently amended): A recombinant LK8 polypeptide consisting of amino acid sequence of SEQ ID NO:8, ~~and having anti-angiogenic activity.~~

Claim 4 (currently amended): A recombinant LK68 polypeptide consisting of amino acid sequence of SEQ ID NO:2, ~~and having anti-angiogenic activity.~~

Claim 5 (canceled)

Claim 6 (canceled)

Claim 7 (canceled)

Claim 8 (canceled)

Claim 9 (canceled)

Claim 10 (canceled)

Claim 11 (canceled)

Claim 12 (canceled)

Claim 13 (canceled)

Claim 14 (canceled)

Claim 15 (canceled)

Claim 16 (canceled)

Claim 17 (canceled)

Claim 18 (withdrawn): A method for treating angiogenesis-mediated disease which comprises administering therapeutically effective amount of LK68 polypeptide to a human or animal.

Claim 19 (withdrawn): The method for treating angiogenesis-mediated disease of claim 18, wherein the angiogenesis-mediated disease is cancer, rheumatoid arthritis, psoriasis, or ocular angiogenic disease.

Claim 20 (previously presented): A composition comprising the polypeptide according to claim 1, and a pharmaceutically acceptable carrier thereof.

Claim 21 (previously presented): A composition comprising the polypeptide according to claim 2, and a pharmaceutically acceptable carrier thereof.

Claim 22 (previously presented): A composition comprising the polypeptide according to claim 3, and a pharmaceutically acceptable carrier thereof.

Claim 23 (previously presented): A composition comprising the polypeptide according to claim 4, and a pharmaceutically acceptable carrier thereof.

Claim 24 (previously presented): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 1.

Claim 25 (previously presented): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 2.

Claim 26 (previously presented): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 3.

Claim 27 (previously presented): A method for inhibiting endothelial cell migration comprising contacting a population of endothelial cells with the polypeptide according to claim 4.

Claim 28 (previously presented): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 1.

Claim 29 (previously presented): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 2.

Claim 30 (previously presented): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 3.

Claim 31 (previously presented): A method of reducing tumor growth comprising contacting the tumor with the polypeptide according to claim 4.

Claim 32 (previously presented): A method for inhibiting endothelial cell proliferation comprising contacting a population of endothelial cells with the polypeptide according to claim 4.

Claim 33 (previously presented): A method of inhibiting growth of capillaries comprising contacting the polypeptide according to claim 4 with a region of capillary formation.